AliveCor, a leader in AI-driven cardiology, has introduced the KAI™ 12L AI technology and the Kardia™ 12L ECG System, both of which have recently received clearance from the U.S. Food and Drug Administration (FDA).
This groundbreaking AI technology can identify life-threatening cardiac conditions, including heart attacks, using a reduced leadset, marking a significant advancement in the field.
The Kardia 12L ECG System is the world’s first handheld 12-lead electrocardiogram (ECG) system powered by AI, featuring a unique single-cable configurationand utilizes advanced deep neural network algorithms, trained on over 1.75 million ECGs from top U.S. medical centers.
This AI can detect 35 different cardiac conditions, including 14 arrhythmias and 21 morphologies, such as acute myocardial infarction (MI) and other forms of cardiac ischemia.
It integrates seamlessly with compatible devices like the Kardia 12L ECG System, making precise heart data more accessible across various healthcare environments.
As the first FDA-cleared AI capable of detecting heart attacks using a reduced leadset, KAI 12L provides determinations across a broad range of conditions.
The Kardia 12L ECG System requires only a single cable with five electrodes to capture eight high-quality diagnostic leads, offering performance on par with the best ECG analysis systems available today.
This helps providers in quickly diagnosing cardiac conditions while improving the patient experience. Weighing just 0.3 pounds and powered by a battery, the Kardia 12L is highly portable and convenient, easily fitting into a pocket.
Its compact design makes the process less invasive, requiring minimal training, and makes 12-lead ECG data accessible to more healthcare providers across various clinical settings, including primary and urgent care offices, employer clinics, and under-resourced or rural areas.
Source: https://alivecor.com/press/press_release/alivecor-launches-kardia-12l-a-first-of-its-kind-ai-powered-12-lead-ecg-system
